Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NR2B NMDA Antagonist CP-101, 606 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| NR2B NMDA Antagonist CP-101,606 (traxoprodil) | DRUG | - |
Inclusion Criteria: * 30- 80-year-old PD patients (UK Parkinson's Disease Brain Bank criteria) with a Hoehn \& Yahr stage score of 2-5 in the "off" state. Exclusion Criteria: * Subjects with evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal...
NR2B NMDA Antagonist CP-101,606 is an investigational small molecule being studied for the treatment of Parkinson's Disease. It is a Phase 2 investigational drug, meaning it has not been approved by regulatory authorities and is still in clinical development. Its use is limited to clinical trials.
NR2B NMDA Antagonist CP-101,606 targets the NR2B subunit of the NMDA receptor. As an antagonist, it blocks the activity of this receptor, which is involved in neurological signaling. This mechanism is being explored for its potential effects in Parkinson's Disease.
NR2B NMDA Antagonist CP-101,606 is being developed by Pfizer, Inc., a biopharmaceutical company listed on the New York Stock Exchange under the ticker symbol PFE. The drug is currently in Phase 2 clinical development for Parkinson's Disease.
NR2B NMDA Antagonist CP-101,606 is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied in clinical trials. The drug is being evaluated for the treatment of Parkinson's Disease.
NR2B NMDA Antagonist CP-101,606 has one completed clinical trial, identified as NCT00163085. This Phase 2 study, titled 'The Effects of an NR2B NMDA Antagonist, CP-101,606, in Patients With Parkinson's Disease,' enrolled 12 participants in the United States. The trial was randomized and double-blind.